FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.
What happened
FDA inspected Revive Rx's Houston pharmacy from January 27, 2025, to February 7, 2025, and issued a Form FDA 483 (inspection observations). The investigator found sterile drug products exposed to worse than required cleanroom air quality, microbial contamination in the sterile processing area, and inadequate sterility process tests, airflow studies, and cleanroom monitoring. FDA reviewed the firm's March 2025 responses and found several corrective actions deficient or missing supporting documentation.
What FDA found
Sterile drug products were exposed to air worse than the required cleanroom quality.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm did not adequately evaluate or correct microbial contamination found in the sterile processing area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Sterility process tests were not run under the most challenging conditions, so FDA lacks assurance the firm can make sterile drugs safely.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Airflow studies under dynamic conditions were inadequate to show one-way airflow in the sterile processing area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to sterilize certain equipment by routine sterilization cycles and to protect it from contamination on air lines and vents.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Routine cleanroom monitoring in the sterile processing area was inadequate, including inside certain units.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
What FDA wants
FDA asks Revive Rx to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and include related documentation; if it cannot complete the work in that time, it must explain the delay and give a timeline.
Who should pay attention
- patients receiving compounded sterile drugs
- healthcare providers who prescribe or administer compounded sterile drugs
- compounding pharmacies and facilities that make sterile drugs
This is a summary. Read the original letter on fda.gov.